Management of Complications Related to Central Venous Catheters in Cancer Patients: An Update

Abstract

Central venous catheters (CVCs) are important for the treatment of patients with cancer, especially in the perioperative and palliative care settings. These devices not only allow for the administration of chemotherapy, parenteral nutrition, and other intravenous therapies, but they may also improve the patients' quality of life by reducing the need for repeated peripheral venipunctures. Thrombotic and infectious complications are common, especially in the long-term use of CVCs. There are different types of thrombotic complications associated with CVCs, that is, a thrombotic occlusion of the catheter, a mural thrombus at the catheter tip and classical deep vein thrombosis, which occurs most frequently in the upper extremity where the majority of long-term catheters are inserted. Infections are common complications associated with CVCs. Patients with cancer who receive intensive chemotherapy and those patients who undergo hematopoietic stem cell transplantation have a markedly increased risk for insertion site and bloodstream infections. In this review, the epidemiology and risk factors that predispose patients to CVC-related thrombosis and infection are discussed. The diagnostic and therapeutic options according to the published data and the current guidelines are summarized and data for establishing primary and secondary preventative strategies are provided.

Keywords

central venous catheter - cancer - thrombosis - infection

• References

• 1 Schiffer CA, Mangu PB, Wade JC , et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31 (10) 1357-1370
• 2 Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13 (1) 233-238
• 3 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21 (19) 3665-3675
• 4 Mueller BU, Skelton J, Callender DP , et al. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992; 10 (12) 1943-1948
• 5 Bonizzoli M, Batacchi S, Cianchi G , et al. Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients. Intensive Care Med 2011; 37 (2) 284-289
• 6 Turcotte S, Dubé S, Beauchamp G. Peripherally inserted central venous catheters are not superior to central venous catheters in the acute care of surgical patients on the ward. World J Surg 2006; 30 (8) 1605-1619
• 7 Saber W, Moua T, Williams EC , et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9 (2) 312-319
• 8 Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev 2012; 3: CD004084
• 9 Biffi R, Orsi F, Pozzi S , et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20 (5) 935-940
• 10 O'Grady NP, Alexander M, Burns LA , et al; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52 (9) e162-e193
• 11 van de Wetering MD, van Woensel JB. Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients. Cochrane Database Syst Rev 2007; 1 (1) CD003295
• 12 Luciani A, Clement O, Halimi P , et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220 (3) 655-660
• 13 Lavau-Denes S, Lacroix P, Maubon A , et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol 2013; 72 (1) 65-73
• 14 Verso M, Agnelli G, Kamphuisen PW , et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008; 3 (2) 117-122
• 15 Lee AY, Levine MN, Butler G , et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006; 24 (9) 1404-1408
• 16 Peris A, Zagli G, Bonizzoli M , et al. Implantation of 3951 long-term central venous catheters: performances, risk analysis, and patient comfort after ultrasound-guidance introduction. Anesth Analg 2010; 111 (5) 1194-1201
• 17 Cotogni P, Pittiruti M, Barbero C, Monge T, Palmo A, Boggio Bertinet D. Catheter-related complications in cancer patients on home parenteral nutrition: a prospective study of over 51,000 catheter days. JPEN J Parenter Enteral Nutr 2013; 37 (3) 375-383
• 18 Di Nisio M, Ferrante N, De Tursi M , et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104 (5) 1049-1054
• 19 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease. 9^th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e494S
• 20 Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119 (3) 648-655
• 21 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
• 22 Barry E, DeAngelo DJ, Neuberg D , et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25 (7) 813-819
• 23 Palumbo A, Rajkumar SV, Dimopoulos MA , et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22 (2) 414-423
• 24 van Marion AM, Auwerda JJ, Lisman T , et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008; 32 (7) 1078-1084
• 25 Cives M, Milano A, Dammacco F, Silvestris F. Lenalidomide in multiple myeloma: current experimental and clinical data. Eur J Haematol 2012; 88 (4) 279-291
• 26 Barni S, Labianca R, Agnelli G , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179
• 27 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
• 28 Onitilo AA, Doi SA, Engel JM, Glurich I, Johnson J, Berg R. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res 2012; 130 (1) 27-31
• 29 Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115 (19) 4442-4449
• 30 Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK. Thrombosis and cancer. Nat Rev Clin Oncol 2012; 9 (8) 437-449
• 31 Marnejon T, Angelo D, Abu Abdou A, Gemmel D. Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters. J Vasc Access 2012; 13 (2) 231-238
• 32 Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag 2013; 9: 207-228
• 33 Baskin JL, Pui CH, Reiss U , et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374 (9684) 159-169
• 34 Toure A, Chambrier C, Vanhems P, Lombard-Bohas C, Souquet JC, Ecochard R. Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients. Clin Nutr 2013; 32 (6) 1050-1054
• 35 Touré A, Vanhems P, Lombard-Bohas C , et al. Totally implantable central venous access port infections in patients with digestive cancer: incidence and risk factors. Am J Infect Control 2012; 40 (10) 935-939
• 36 Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27 (29) 4858-4864
• 37 Borchardt RA, Raad I. Bloodstream infections: the risks and benefits of intravascular catheters. JAAPA 2012; 25 (8) 21-22
• 38 van Rooden CJ, Schippers EF, Barge RM , et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23 (12) 2655-2660
• 39 Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999; 25 (2) 147-155
• 40 Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002; 30 (4) 908-912
• 41 Mitchell MD, Anderson BJ, Williams K, Umscheid CA. Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. J Adv Nurs 2009; 65 (10) 2007-2021
• 42 Muslimani AA, Ricaurte B, Daw HA. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol 2007; 82 (7) 652-655
• 43 Boraks P, Seale J, Price J , et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101 (3) 483-486
• 44 Monreal M, Alastrue A, Rull M , et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75 (2) 251-253
• 45 Couban S, Goodyear M, Burnell M , et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23 (18) 4063-4069
• 46 Karthaus M, Kretzschmar A, Kröning H , et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17 (2) 289-296
• 47 Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Büller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5 (9) 1878-1882
• 48 Verso M, Agnelli G, Bertoglio S , et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23 (18) 4057-4062
• 49 Young AM, Billingham LJ, Begum G , et al; WARP Collaborative Group, UK. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373 (9663) 567-574
• 50 Akl EA, Vasireddi SR, Gunukula S , et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev 2011; 4 (4) CD006468
• 51 Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5 (12) 2552-2554
• 52 Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99 (1) 38-43
• 53 Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters—a reappraisal of the evidence. Br J Cancer 2006; 94 (2) 189-194
• 54 Kahn SR, Lim W, Dunn AS , et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e195S-e226S
• 55 Akl EA, Gunukula S, Barba M , et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011; 4 (4) CD006652
• 56 McLaws ML, Burrell AR. Zero risk for central line-associated bloodstream infection: are we there yet?. Crit Care Med 2012; 40 (2) 388-393
• 57 Covey AM, Toro-Pape FW, Thornton RH , et al. Totally implantable venous access device placement by interventional radiologists: are prophylactic antibiotics necessary?. J Vasc Interv Radiol 2012; 23 (3) 358-362
• 58 Timsit JF, Schwebel C, Bouadma L , et al; Dressing Study Group. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA 2009; 301 (12) 1231-1241
• 59 Weber JM, Sheridan RL, Fagan S, Ryan CM, Pasternack MS, Tompkins RG. Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population. J Burn Care Res 2012; 33 (4) 539-543
• 60 Raad I, Mohamed JA, Reitzel RA , et al. Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi. Antimicrob Agents Chemother 2012; 56 (2) 935-941
• 61 Gilbert RE, Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis 2008; 21 (3) 235-245
• 62 Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006; 43 (4) 474-484
• 63 Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant 2003; 18 (12) 2688-2690
• 64 Slobbe L, Doorduijn JK, Lugtenburg PJ , et al. Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS ONE 2010; 5 (5) e10840
• 65 Dümichen MJ, Seeger K, Lode HN , et al. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. J Hosp Infect 2012; 80 (4) 304-309
• 66 Rosenblatt J, Reitzel R, Dvorak T, Jiang YY, Hachem R, Raad II. Glyceryl trinitrate complements citrate and ethanol in a novel antimicrobial catheter lock solution. Antimicrob Agents Chemother 2013; 57: 3555-3560
• 67 Maki DG, Ash SR, Winger RK, Lavin P ; AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med 2011; 39 (4) 613-620
• 68 Vescia S, Baumgärtner AK, Jacobs VR , et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008; 19 (1) 9-15
• 69 Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER ; COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12 (8) 951-955
• 70 Deitcher SR, Fesen MR, Kiproff PM , et al; Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20 (1) 317-324
• 71 Linnemann B, Lindhoff-Last E. Risk factors, management and primary prevention of thrombotic complications related to the use of central venous catheters. Vasa 2012; 41 (5) 319-332
• 72 Levitan N, Dowlati A, Remick SC , et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (5) 285-291
• 73 Linnemann B, Meister F, Schwonberg J, Schindewolf M, Zgouras D, Lindhoff-Last E ; MAISTHRO registry. Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry. Thromb Haemost 2008; 100 (3) 440-446
• 74 Muñoz FJ, Mismetti P, Poggio R , et al; RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133 (1) 143-148
• 75 Spencer FA, Emery C, Lessard D, Goldberg RJ ; Worcester Venous Thromboembolism Study. Upper extremity deep vein thrombosis: a community-based perspective. Am J Med 2007; 120 (8) 678-684
• 76 Mandalà M, Curigliano G, Bucciarelli P , et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15 (4) 590-593
• 77 Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89 (2) 201-206
• 78 Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6 (1) 70-75
• 79 De Cicco M, Matovic M, Balestreri L , et al. Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thromb Res 1995; 78 (2) 127-137
• 80 Kucher N. Clinical practice. Deep venous thrombosis of the upper extremities. N Engl J Med 2011; 364: 861-869
• 81 Mai C, Hunt D. Upper-extremity deep venous thrombosis: a review. Am J Med 2011; 124 (5) 402-407
• 82 Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356 (18) 1862-1869
• 83 Arnhjort T, Persson LM, Rosfors S, Ludwigs U, Lärfars G. Primary deep vein thrombosis in the upper limb: A retrospective study with emphasis on pathogenesis and late sequelae. Eur J Intern Med 2007; 18 (4) 304-308
• 84 Baarslag HJ, Koopman MM, Hutten BA , et al. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004; 15 (8) 503-507
• 85 Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006; 117 (6) 609-614
• 86 Hingorani A, Ascher E, Marks N , et al. Morbidity and mortality associated with brachial vein thrombosis. Ann Vasc Surg 2006; 20 (3) 297-300
• 87 Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110 (5) 566-570
• 88 Monreal M, Raventos A, Lerma R , et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. Thromb Haemost 1994; 72 (4) 548-550
• 89 Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival after a first venous thrombosis of the upper extremities. Circulation 2004; 110: 566-572
• 90 Bates SM, Jaeschke R, Stevens SM , et al; American College of Chest Physicians. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e351S-e418S
• 91 Debourdeau P, Farge D, Beckers M , et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11 (1) 71-80
• 92 Linnemann B, Lindhoff-Last E. [Management of catheter-related upper extremity deep vein thrombosis]. Zentralbl Chir 2013; 138 (Suppl. 02) e86-e94
• 93 Di Nisio M, Van Sluis GL, Bossuyt PM, Büller HR, Porreca E, Rutjes AW. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost 2010; 8 (4) 684-692
• 94 Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3 (11) 2409-2419
• 95 Baarslag HJ, Van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004; 45 (1) 38-43
• 96 Kim H, Chung JW, Park JH , et al. Role of CT venography in the diagnosis and treatment of benign thoracic central venous obstruction. Korean J Radiol 2003; 4 (3) 146-152
• 97 Constans J, Salmi LR, Sevestre-Pietri MA , et al. A clinical prediction score for upper extremity deep venous thrombosis. Thromb Haemost 2008; 99 (1) 202-207
• 98 Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006; 17 (3) 225-226
• 99 Kovacs MJ, Kahn SR, Rodger M , et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5 (8) 1650-1653
• 100 Savage KJ, Wells PS, Schulz V , et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999; 82 (3) 1008-1010
• 101 Streiff MB ; National Comprehensive Cancer Center Network. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl. 02) S128-S133
• 102 Farge D, Debourdeau P, Beckers M , et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11 (1) 56-70
• 103 Lee AYY, Levine MN, Baker RI , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
• 104 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A , et al; RIETE Investigators. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (Suppl. 02) S58-S61
• 105 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
• 106 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
• 107 Jones MA, Lee DY, Segall JA , et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51 (1) 108-113
• 108 Sullivan VV, Wolk SW, Lampman RM, Prager RL, Hankin FM, Whitehouse Jr WM. Upper extremity venous gangrene following coronary artery bypass. A case report and review of the literature. J Cardiovasc Surg (Torino) 2001; 42 (4) 551-554
• 109 Chopra V, Anand S, Krein SL, Chenoweth C, Saint S. Bloodstream infection, venous thrombosis, and peripherally inserted central catheters: reappraising the evidence. Am J Med 2012; 125 (8) 733-741
• 110 Chopra V, Anand S, Hickner A , et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 2013; 382 (9889) 311-325
• 111 Boersma RS, Jie KS, Verbon A, van Pampus EC, Schouten HC. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 2008; 19 (3) 433-442
• 112 Rodríguez L, Ethier MC, Phillips B, Lehrnbecher T, Doyle J, Sung L. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review. Support Care Cancer 2012; 20 (12) 3261-3267
• 113 Mermel LA, Allon M, Bouza E , et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49 (1) 1-45
• 114 Béraud G, Seguy D, Alfandari S , et al. Factors associated with recurrence of catheter-related bloodstream infections in home parenteral nutrition patients. Eur J Clin Microbiol Infect Dis 2012; 31 (11) 2929-2933